Latest Period
Q2 2026
Security Snapshot
Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) Institutional Ownership
CUSIP: 140755307
13F Institutional Holders and Ownership History from Q2 2025 to Q2 2026
Institutions Reporting
57
Shares (Excl. Options)
2,226,674
Price
$1.90
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- TVRD on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,226,674
- Total 13F value
- $4,243,229
- Portfolio coverage rank
- 0%
- Share change
- -473,616
- Value change
- -$1,131,712
- Number of holders
- 57
- Shares outstanding
- 9,470,889
- SEC-reported price per share
- $2.10
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 140755307.
- 57 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 66 to 57 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $8,596,315 to $4,243,229.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 57 institutions filings for Q2 2026.
Security key
140755307
Latest holder period
Q2 2026
13F holders
57
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
TVRD full holder history
Tvardi Therapeutics, Inc. SEC filings
Tvardi Therapeutics, Inc. company facts
Tvardi Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 140755307:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
TVRD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Slate Path Capital LP | 7.5% | $19,257,627 | 704,118 | Slate Path Capital LP | 30 Jun 2025 | |||
| DePinho Ronald A | 4.5% | $1,939,164 | 426,190 | Ronald A. DePinho | 31 Dec 2025 | |||
| Vifor (International) Ltd | 2.2% | $4,725,695 | 205,465 | Vifor (International) Ltd. | 15 Apr 2025 |
As of 30 Jun 2026, 57 institutional investors reported holding 2,226,674 shares of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD). This represents 24% of the company’s total 9,470,889 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
23%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Slate Path Capital LP | 7.4% | 704,118 | 0% | 0.02% | $1,337,824 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 344,382 | -0.09% | 0% | $654,326 |
| AMERICAN FINANCIAL GROUP INC | 2.4% | 223,659 | 0% | 0.15% | $424,952 |
| UBS Group AG | 1.2% | 111,133 | +120% | 0% | $211,153 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 1.1% | 101,034 | 0% | 0% | $191,965 |
| BlackRock, Inc. | 1% | 95,478 | -75% | 0% | $181,408 |
| RENAISSANCE TECHNOLOGIES LLC | 0.97% | 91,409 | -0.75% | 0% | $173,677 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.95% | 90,350 | -50% | 0% | $171,741 |
| MORGAN STANLEY | 0.82% | 77,845 | +6.8% | 0% | $147,905 |
| Duncan Williams Asset Management, LLC | 0.67% | 63,241 | 0% | 0.03% | $120,158 |
| VANGUARD FIDUCIARY TRUST CO | 0.47% | 44,710 | -4.6% | 0% | $84,949 |
| Russell Investments Group, Ltd. | 0.46% | 43,228 | +85% | 0% | $82,133 |
| STATE STREET CORP | 0.36% | 33,900 | -65% | 0% | $64,410 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.35% | 33,165 | 0% | $63,014 | |
| AQR CAPITAL MANAGEMENT LLC | 0.29% | 27,096 | -36% | 0% | $51,483 |
| NORTHERN TRUST CORP | 0.23% | 21,836 | -56% | 0% | $41,489 |
| Savant Capital, LLC | 0.21% | 19,462 | 0% | $49,434 | |
| GSA CAPITAL PARTNERS LLP | 0.19% | 17,885 | 0% | $34,000 | |
| DIADEMA PARTNERS LP | 0.18% | 16,607 | 0.01% | $31,553 | |
| XTX Topco Ltd | 0.16% | 14,868 | 0% | $28,249 | |
| BROWN ADVISORY INC | 0.12% | 11,200 | 0% | $21,280 | |
| Arax Advisory Partners | 0.12% | 11,003 | +32% | 0% | $20,906 |
| Qube Research & Technologies Ltd | 0.11% | 10,210 | 0% | $19,399 | |
| Persistent Asset Partners Ltd | 0.04% | 4,253 | 0% | $8,081 | |
| PNC Financial Services Group, Inc. | 0.04% | 3,518 | +578% | 0% | $6,685 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q2 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 2,226,674 | $4,243,229 | -$1,131,712 | $1.90 | 57 |
| 2026 Q1 | 2,703,203 | $8,596,315 | -$546,130 | $3.18 | 66 |
| 2025 Q4 | 2,824,911 | $12,111,919 | -$18,315,547 | $4.30 | 64 |
| 2025 Q3 | 2,603,814 | $101,367,779 | +$26,943,937 | $38.97 | 64 |
| 2025 Q2 | 1,922,982 | $44,387,703 | +$44,380,704 | $23.33 | 48 |